Xenon Pharmaceuticals Inc. (XENE)
Xenon Pharmaceuticals Q2 Earnings Call Highlights
10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter.
XENE's Q2 Loss Narrower Than Expected, Sales Nil, Pipeline in Focus
Xenon posts a narrower-than-expected Q2 loss as azetukalner advances toward a planned FDA filing, while its cash runway is expected to support operations into 2029.
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q2 2026 Earnings Call Transcript
Xenon Pharmaceuticals: Azetukalner Has Shifted From Binary Science To Commercial Execution
Xenon Pharmaceuticals (XENE) is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is progressing toward a Q3 2026 NDA filing. The company has a cash runway through 2029, supporting ongoing Phase 3 trials in MDD, bipolar depression, and pain, and is building a commercial infrastructure.
Xenon Pharmaceuticals Stock Gains 22% in Six Months: Here's Why
XENE's shares climb 22% in six months as azetukalner delivers strong phase III epilepsy data and advances across multiple late-stage studies.
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Inc. (XENE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Xenon Pharmaceuticals Q1 Earnings Call Highlights
Xenon Pharmaceuticals NASDAQ: XENE said it is preparing to submit a new drug application to the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner, its investigational anti-seizure medicine, after reporting positive Phase 3 data in focal onset seizures during the first quarter.
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon Pharmaceuticals Inc. (XENE) Q1 2026 Earnings Call Transcript
Xenon's Phase 3 Supports A 'Buy' Despite Its Premium
Xenon Pharmaceuticals Inc.'s bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. Azetukalner's differentiated Kv7 mechanism, once-daily dosing, and no-titration profile may help its future adoption, especially for polytreated epilepsy patients. XENE plans its NDA submission in Q3 2026, which would be a key transition toward potential commercialization and revenues.
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
XENE shares gain 20% in 3 months as positive phase III data for epilepsy drug azetukalner and pipeline progress boost outlook and investor confidence.
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
Driehaus Capital Management increased its XENE stake by 369,577 shares in the fourth quarter; the estimated transaction value was $15.52 million. Meanwhile, the quarter-end position value rose by $36.03 million, reflecting both trading and price appreciation.
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Xenon stock soars after phase III X-TOLE2 shows azetukalner significantly cuts focal onset seizure frequency. The company plans an NDA filing in third-quarter 2026.
